Through its Quest for Health Equity (Q4HE) initiative, Quest recently provided no-cost preventive health testing for approximately 80 individuals attending the 8th annual I-HEAL Community Wellness Day, held in in Cleveland, Miss. Quest Supports Underserved Communities in the Mississippi Delta Under a definitive agreement, Quest will acquire select assets of Northern Light Health's outreach laboratory services business and manage nine of Northern Light Health's hospital laboratories, along with its cancer center laboratory in Brewer, Maine. The collaboration will enable physicians and patients throughout Maine to benefit from access to Quest's industry-leading and highly innovative test menu, network of patient access sites throughout the state, broad health plan coverage, and lower out-of-pocket costs for many services. Quest Diagnostics and Northern Light Health Form Strategic Laboratory Collaboration to Improve Access to Affordable Diagnostic Services in Maine The report is a reminder that while illicit fentanyl is responsible for most overdose deaths, misuse of controlled medications continues to be a public health challenge. Amphetamines use surged 5-fold and dangerous drug combing increased over the past decade. In 2021, nearly half (49%) of patients prescribed opioids, benzodiazepines, amphetamines and other controlled medications by a physician showed signs of dangerous drug combing and other forms of misuse, based on clinical drug results, compared to 60% to 2012. Quest Diagnostics recently released its latest Health Trends® report, "Drug Misuse in America 2022: A Decade Lost to the Drug Crisis." Based on insights from more than 20 million deidentified clinical drug tests* over 10 years, the report reveals that while progress has been made in the last decade, large percentages of patients of all ages and both sexes still misuse their prescription drugs. To schedule an interview, email in Two Patients Tested Misuse Prescription Drugs, Finds 10th Annual Quest Diagnostics Health Trends® Report Racke has authored more than 200 peer-reviewed papers, book chapters, and reviews on the pathogenesis of neuroimmunology diseases, and has served on the editorial review boards of numerous peer-reviewed journals, including JAMA Neurology. This includes providing expertise for the development of a blood test Quest launched last year to aid in assessing the risk of Alzheimer’s disease. Dr Racke’s expertise includes supporting the development of laboratory tests to identify and monitor therapeutic response for neurologic disorders, such as Alzheimer’s disease and multiple sclerosis. Racke is a leader in the field of neurology and neuroimmunology with over three decades of leadership experience in academia and clinical practice. For any questions, or to be added or removed from the distribution list, please email Matter Expert of the Month: Dr. Instead, this media statement will transition to a monthly digest of the latest news on Quest’s innovations, business developments and people. To receive these media updates, please email and Photos:īeginning February 2023, Quest Diagnostics plans to discontinue providing a monthly COVID-19 media statement, including monthly COVID-19 volume and turnaround time figures. Please check back to this page periodically for the latest information.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |